Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, Yi‐Long Wu, Yuankai Shi et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 9
Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trialXiaochu Man, Jie Huang, Shujuan Sun et al.|Clinical and Translational Medicine|2024Cited by 6